Cooperative international neuromuscular research group duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in duchenne muscular dystrophy

Muscle and Nerve

Volumn 50, Issue 2, 2014, Pages 250-256

  Spurney, Christopher ^a   Shimizu, Reiko ^b   Morgenroth, Lauren P ^a   Kolski, Hanna ^c   Gordish Dressman, Heather ^a   Clemens, Paula R ^b,d   Cregan, Michelle ^e   Goude, Erica ^e   Glick, Merete ^e   Johnson, Linda ^e   Han, Jay ^e   Joyce, Nanette ^e   Kilmer, David ^e   Nicorici, Alina ^e   Chidambaranathan, C ^f,g   Kumar, Suresh ^f,g   Eliasoph, Laila ^h   Hosaki, Elizabeth ^h   Gonzales, Angela ^h   Harris, Vivienne ^h   Chiu, Angela ⁱ   Thannhauser, Jennifer ⁱ   Walker, Lori ⁱ   Wright, Caitlin ⁱ   Yousefi, Mehrnaz ⁱ   Alhander, Anne Christine ^j   Wahlgren, Lisa ^j   Ekstrom, Anne Berit ^j   Kroksmark, Anna Karin ^j   Sterky, Ulrika ^j   Birkmeier, Marissa ^a   Duong, Tina ^a,x   Kaminski, Sarah ^a   Carroll, Kate ^k   DeValle, Katy ^k   Kennedy, Rachel ^k   Kornberg, Andrew ^k   Rodriguez, Victoria ^k   Villano, Dani ^k   Leve, Adina Bar ^l   Wisband, Elana ^l   Yaffe, Debbie ^l   Andreone, Luz ^m   Corderi, Jose ^m   Mesa, Lilia ^m   Levi, Lorena ^m   Coleman Wood, Krista ⁿ   Hoffman, Ann ⁿ   Korn Petersen, Wendy ⁿ   Kuntz, Nancy ⁿ   Selcen, Duygu ⁿ   Abdel Hamid, Hoda ^o   Bise, Christopher ^o   Craig, Ann ^o   Nguyen, Casey ^o   Weimer, Jason ^o   Al Lozi, M ^p   Florence, Julaine ^p   Golumbak, Paul ^p   Lopate, Glenn ^p   Malane, Justin ^p   Malkus, Betsy ^p   Renna, Renee ^p   Schierbacker, Jeanine ^p   Seiner, Catherine ^p   Wulf, Charlie ^p   Blair, Susan ^q   Grillo, Barbara ^q   Jones, Karen ^q   Monasterio, Eugenio ^q   Barrett Adair, Meegan ^r   Clift, Judy ^r   Feliciano, Cassandra ^r   Young, Rachel ^r   Rose, Kristy ^s   Webster, Richard ^s   Wicks, Stephanie ^s   Chen, Lucia ^c   Kennedy, Cameron ^c   Deliz, Brenda ^t   Espada, Sheila ^t   Fuste, Pura ^t   Luciano, Carlos ^t   Beneggi, Maria ^u   Capone, Luca ^u   Molteni, Alessandro ^u   Morettini, Valentina ^u   Gupta, Anjali ^v   McNeil, Robert ^v   Erickson, Amy ^w   Margolis, Marcia ^w   Naughton, Cameron ^w   Parry, Gareth ^w   Walk, David ^w   Arrieta, Adrienne ^x   Bartley, Naomi ^x   Canelos, Paola ^x   Casper, Robert ^x   Cnaan, Avital ^x   Hu, Fengming ^x   Sund, Zoë ^x   Zimmerman, Angela ^x   more..

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Sundaram Medical Foundation   (India)

^g Apollo Children s Hospital   (India)

^h HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITAL   (Canada)

ⁱ ALBERTA CHILDREN'S HOSPITAL   (Canada)

^j QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^k ROYAL CHILDREN'S HOSPITAL   (Australia)

^l HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^m HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

ⁿ MAYO CLINIC   (United States)

^o CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^p WASHINGTON UNIVERSITY   (United States)

^q Children s Hospital of Virginia   (United States)

^r UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^s CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^t UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^u Centro Clinico NEMO   (Italy)

^v TEXAS CHILDREN S HOSPITAL   (United States)

^w UNIVERSITY OF MINNESOTA   (United States)

^x The CINRG Coordinating Center   (United States)

more..

Author keywords

Cardiomyopathy; Duchenne muscular dystrophy; Echocardiogram; Glucocorticoid; Natural history

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID;

ADOLESCENT; ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CHILD; CLINICAL STUDY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; LEG SWELLING; MAJOR CLINICAL STUDY; MUSCLE BIOPSY; PRIORITY JOURNAL; TACHYCARDIA; THORAX PAIN;

CARDIOMYOPATHY; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAM; GLUCOCORTICOID; NATURAL HISTORY;

ADOLESCENT; ADULT; AGE FACTORS; BIOMEDICAL RESEARCH; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERNATIONAL COOPERATION; MALE; MUSCULAR DYSTROPHY, DUCHENNE; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84904674913     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24163     Document Type: Article

References (36)

1. Emery AE. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1991;1:19-29.
2. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71:304-313.
3. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
4. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
5. Gilroy J, Cahalan JL, Berman R, Newman M. Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy. Circulation 1963;27:484-493.
6. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003;13:166-172.
7. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990;26:271-277.
8. McDonald CM, Henricson EK, Abresch R, Han J, Escolar D, Florence J, et al. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study-a longitudinal natural history study in the era of glucocorticoid therapy: design of the protocol and methods. Muscle Nerve 2013;48:32-54.
9. Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, et al. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically-meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testingand other commonly used clinical trial outcome measures. Muscle Nerve 2013;48:55-67.
10. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855-857.
11. Houde S, Filiatrault M, Fournier A, Dube J, D'Arcy S, Berube D, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200-206.
12. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008;18:365-370.
13. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 2005;26:768-771.
14. Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012;110:98-102.
15. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103.
16. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981;4:186-197.
17. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol;9:177-189.
18. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol;9:77-93.
19. Vignos PJ Jr, Spencer GE Jr, Archibald KC. Management of progressive muscular dystrophy in childhood. JAMA 1963;184:89-96.
20. Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone ST, et al. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life. Am J Cardiol 2006;98:825-827.
21. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154:596-602.
22. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 1999;137:895-902.
23. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112:2799-2804.
24. Rhodes J, Margossian R, Darras BT, Colan SD, Jenkins KJ, Geva T, et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008;29:343-351.
25. Kirchmann C, Kececioglu D, Korinthenberg R, Dittrich S. Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. Pediatr Cardiol 2005;26:66-72.
26. Ahmad M, Sanderson JE, Dubowitz V, Hallidie-Smith KA. Echocardiographic assessment of left ventricular function in Duchenne's muscular dystrophy. Br Heart J 1978;40:734-740.
27. Farah MG, Evans EB, Vignos PJ Jr. Echocardiographic evaluation of left ventricular function in Duchenne's muscular dystrophy. Am J Med 1980;69:248-254.
28. Gulati S, Saxena A, Kumar V, Kalra V. Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. Indian J Pediatr 2005;72:389-393.
29. Melacini P, Vianello A, Villanova C, Fanin M, Miorin M, Angelini C, et al. Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy. Neuromuscul Disord 1996;6:367-376.
30. Ramaciotti C, Scott WA, Lemler MS, Haverland C, Iannaccone ST. Assessment of cardiac function in adolescents with Duchenne muscular dystrophy: importance of neurohormones. J Child Neurol 2002;17:191-194.
31. Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003;91:769-772.
32. van Bockel EA, Lind JS, Zijlstra JG, Wijkstra PJ, Meijer PM, van den Berg MP, et al. Cardiac assessment of patients with late stage Duchenne muscular dystrophy. Netherlands Heart J 2009;17:232-237.
33. Barber BJ, Andrews JG, Lu Z, West NA, Meaney FJ, Price ET, et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 2013;163:1080-1084.
34. Schram G, Fournier A, Leduc H, Dahdah N, Therien J, Vanasse M, et al. all-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 2013;61:948-954.
35. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
36. Politano L, Nigro G. Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta Myol 2012;31:24-30.